Opioid-Withdrawal Beverage Seller Latest Target Of FDA-FTC Joint Enforcement
This article was originally published in The Rose Sheet
Executive Summary
While essentially all products labeled as dietary supplements but marketed with claims to treat diseases or illnesses could be targets of FTC enforcement against unsubstantiated advertising, FDA warnings to firms linked to those products generally don't discuss violations of FTC rules. But the warning to Up-Inya Beverages, like firms previously identified as making opioid-withdrawal claims, included an explanation of how it's in FTC's crosshairs, too.